<DOC>
	<DOCNO>NCT02310464</DOCNO>
	<brief_summary>The primary purpose clinical trial investigate safety tolerability escalate dos OBI-833/OBI-821 subject metastatic incurable solid tumor , gastric , lung , colorectal breast cancer . Meanwhile , tumor response humoral immune response , i.e. , anti-Globo H IgG IgM production follow administration OBI-833/OBI-821 assess secondary objective study .</brief_summary>
	<brief_title>Trial Active Immunotherapy With OBI-833 ( Globo H-CRM197 ) Advanced/Metastatic Gastric , Lung , Colorectal Breast Cancer Subjects</brief_title>
	<detailed_description>The First-In-Human clinical trial evaluate safety tolerability three dose OBI-833 ( 10,30 100μg ) along fix dose 100μg OBI-821 adjuvant small number patient ( N=26 ) late stage gastric , colorectal , breast lung cancer . Patients receive total 10 dos subcutaneously 24 week , evaluate safety immune response 24 week treatment period subsequently observe additional 12 week post-treatment . In addition standard battery safety test , evaluation also include immunological response , tumor marker clinical endpoint disease progression free survival ( RECIST 1.1 ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Subjects ≥21 year age 2 . Histologically cytologically confirm diagnosis gastric , lung , colorectal breast cancer file 3 . Subjects recurrent metastatic incurable disease fail respond least one line anticancer standard therapy standard treatment longer effective tolerable . 4 . Measurable disease ( i.e. , present least one measurable lesion per RECIST , version 1.1 . 5 . Performance status : ECOG ≤ 1 6 . Organ Function Requirements Subjects must adequate organ function define : AST/ALT ≤ 3X ULN ( upper limit normal ) AST/ALT ≤ 5X ULN [ underlie liver metastasis ] Total bilirubin ≤ 2.0 X ULN Serum creatinine ≤ 1.5X ULN ANC ≥ 1500 /µL Platelets &gt; 100,000/µL 7 . Subjects childbearing potential must agree use acceptable contraceptive method treatment end study . Subject childbearing potential ( i.e. , permanently sterilize , postmenopausal ) include study . Postmenopausal define 12 month menses without alternative medical cause . 8 . Ability understand willingness sign write informed consent document accord institutional guideline . 1 . Patients receive standard chemotherapy , hormonal target therapy underlie advanced/metastatic cancer . 2 . Subjects pregnant breastfeed entry . 3 . Subjects splenectomy . 4 . Subjects know clinically manifest , symptomatic CNS metastasis . 5 . Subjects HIV infection , active hepatitis B infection active hepatitis C infection . 6 . Subjects autoimmune disorder require iv/oral steroid immunosuppressive immunomodulatory therapy . e.g. , Type 1 juvenile onset diabetes mellitus , antibody positive rheumatoid arthritis , Grave 's disease , Hashimoto 's thyroiditis , lupus , scleroderma , systemic vasculitis , hemolytic anemia , immune mediate thrombocytopenia , etc . 7 . Subjects know uncontrolled intercurrent illness include ongoing active infection , symptomatic congestive heart failure ( NYHA &gt; 2 ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 8 . Subjects follow MEDICATIONS within 4 week prior IP treatment , except permitted therapy list section 7.1 : Chemotherapeutic Agent Immunotherapy [ mAbs , Interferons , Cytokines ( except GCSF ) ] Immunosuppressants ( e.g. , cyclosporin , rapamycin , tacrolimus , rituximab , alemtuzumab , natalizumab , etc. ) . IV/oral steroid except single prophylactic use CT/MRI scan onetime use approve indication . Another investigational drug 9 . Subjects pleural effusion and/or ascites , due malignancy , require paracentesis every 2 week frequently . 10 . Subjects know severe allergy ( e.g. , anaphylaxis ) active inactive ingredient study drug .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>